Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: Results of the COMPASS-1 study

Journal of Clinical Pharmacology

Volumn 49, Issue 11, 2009, Pages 1343-1352

  Gruenig, Ekkehard ^a   Michelakis, Evangelos ^b   Vachiéry, Jean Luc ^c   Vizza, Carmine Dario ^d   Meyer, F Joachim ^a   Doelberg, Martin ^e   Bach, Doris ^e   Dingemanse, Jasper ^e   Galiè, Nazzareno ^f  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c ERASME HOSPITAL   (Belgium)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e ACTELION PHARMACEUTICALS LTD   (Switzerland)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bosentan; Pharmacodynamics; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; NITRIC OXIDE; SILDENAFIL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYSTITIS; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FEMALE; HEADACHE; HEART CATHETERIZATION; HEMODYNAMICS; HUMAN; INSOMNIA; LUNG VASCULAR RESISTANCE; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; PHASE 2 CLINICAL TRIAL; PULMONARY HYPERTENSION; SINGLE DRUG DOSE; SUPRAVENTRICULAR PREMATURE BEAT; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; NITRIC OXIDE; PIPERAZINES; PULMONARY ARTERY; PURINES; SULFONAMIDES; SULFONES; VASODILATOR AGENTS;

EID: 70149121675     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009341182     Document Type: Article

References (37)

1. Badesch DB, Abman SH, Simonneau G., Rubin LJ, McLaughlin VV Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 ; 131: 1917-1928.
2. OĝCallaghan D., Gaine SP Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med. 2007 ; 28: 169-185.
3. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004 ; 351: 1425-1436.
4. Benza RL, Park MH, Keogh A., Girgis RE Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant. 2007 ; 26: 437-446.
5. Tracleer [US prescribing information]. San Francisco: Actelion Pharmaceuticals US ; 2007.
6. Nichols DJ, Muirhead GJ, Harness JA Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002 ; 53 (suppl 1). 5S - 12S.
7. Revatio [US prescribing information]. New York: Pfizer, Inc ; 2007.
8. Clozel M., Hess P., Rey M., Iglarz M., Binkert C., Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood). 2006 ; 231: 967-973.
9. Hoeper MM, Faulenbach C., Golpon H., Winkler J., Welte T., Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004 ; 24: 1007-1010.
10. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007 ; 29: 469-475.
11. Gali N., Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008 ; 371: 2093-2100.
12. Humbert M., Segal ES, Kiely DG, Carlsen J., Schwierin B., Hoeper MM Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007 ; 30: 338-344.
13. Burgess G., Hoogkamer H., Collings L., Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol. 2008 ; 64: 43-50.
14. Dingemanse J., van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet. 2004 ; 43: 1089-1115.
15. Hyland R., Roe EG, Jones BC, Smith DA Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 ; 51: 239-248.
16. Treiber A., Schneiter R., H'Currency signusler S., Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 ; 35: 1400-1407.
17. Paul GA, Gibbs JS, Boobis AR, Abbas A., Wilkins MR Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005 ; 60: 107-112.
18. Galiá N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 ; 25: 2243-2278.
19. Borley NR, Achan V. Instant Physiology. 2 nd ed. Hoboken, NJ: John Wiley ; 2005.
20. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002 ; 105: 2398-2403.
21. Jackson G., Benjamin N., Jackson N., Allen MJ Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999 ; 83: 13C - 20C.
22. Ghofrani HA, Schermuly RT, Rose F., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2003 ; 167: 1139-1141.
23. Leuchte HH, Schwaiblmair M., Baumgartner RA, Neurohr CF, Kolbe T., Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest. 2004 ; 125: 580-586.
24. Ghofrani HA, Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002 ; 136: 515-522.
25. Galie N., Ghofrani HA, Torbicki A., et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353: 2148-2157. (Pubitemid 41653106)
26. Channick RN, Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001 ; 358: 1119-1123.
27. Barst RJ, Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004 ; 169: 441-447.
28. Simonneau G., Rubin LJ, Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008 ; 149: 521-530.
29. Dresser GK, Spence JD, Bailey DG Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 ; 38: 41-57.
30. Lunze K., Gilbert N., Mebus S., et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest. 2006 ; 36 (suppl 3). 32-38.
31. Porhownik NR, Al- Sharif H., Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J. 2008 ; 15: 427-430.
32. Mehrotra N., Gupta M., Kovar A., Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 2007 ; 19: 253-264.
33. King L., Wilkins MR Natriuretic peptide receptors and the heart. Heart. 2002 ; 87: 314-315.
34. Yap LB, Ashrafian H., Mukerjee D., Coghlan JG, Timms PM The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem. 2004 ; 37: 847-856.
35. Souza R., Bogossian HB, Humbert M., et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005 ; 25: 509-513.
36. Weber M., Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006 ; 92: 843-849.
37. Smith DA Induction and drug development. Eur J Pharm Sci. 2000 ; 11: 185-189.